Tags

Type your tag names separated by a space and hit enter

Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients.
Clin Nephrol 1995; 43(4):268-77CN

Abstract

Elevated plasma intermediate density lipoprotein (IDL) is one of the features of uremic dyslipidemia which is potentially atherogenic. We examined the effects of pravastatin, an HMG-CoA reductase inhibitor, on IDL levels as well as other lipoprotein parameters in 19 uremic patients treated with hemodialysis (HD, n = 11) or continuous ambulatory peritoneal dialysis (CAPD, n = 8). The patients were administered 5 mg/day pravastatin for the initial 4 weeks and 10 mg/day for the subsequent 12 weeks. In the analysis of the total subjects, IDL-cholesterol was reduced by 31% as well as low density lipoprotein (LDL)-cholesterol. Cholesterol in very low density lipoprotein (VLDL) also decreased whereas that in high density lipoprotein (HDL) did not. Significant decrease of serum triglycerides was due mainly to reduced IDL- and LDL-triglycerides. Apolipoprotein (apo) A-I did not change, whereas apo A-II, B, C-II, C-III, E, and B/A-I ratio were significantly lowered. Pravastatin did not affect measured activity of lecithin: cholesterol acyltransferase, post-heparin plasma lipoprotein lipase or hepatic triglyceride lipase. HD and CAPD patients responded almost equally to the treatment. IDL elevation was present independent of serum total cholesterol, and it was lowered by pravastatin even in non-hypercholesterolemic subjects. There was no critical adverse effect besides transient and asymptomatic increase of serum creatine kinase level. We conclude that pravastatin can be a safe and effective approach to the management of dyslipidemia in uremic patients who have an elevated level of IDL.

Authors+Show Affiliations

Second Department of Internal Medicine, Osaka City University Medical School, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

7606882

Citation

Nishizawa, Y, et al. "Reduction of Intermediate Density Lipoprotein By Pravastatin in Hemo- and Peritoneal Dialysis Patients." Clinical Nephrology, vol. 43, no. 4, 1995, pp. 268-77.
Nishizawa Y, Shoji T, Emoto M, et al. Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients. Clin Nephrol. 1995;43(4):268-77.
Nishizawa, Y., Shoji, T., Emoto, M., Kawasaki, K., Konishi, T., Tabata, T., ... Morii, H. (1995). Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients. Clinical Nephrology, 43(4), pp. 268-77.
Nishizawa Y, et al. Reduction of Intermediate Density Lipoprotein By Pravastatin in Hemo- and Peritoneal Dialysis Patients. Clin Nephrol. 1995;43(4):268-77. PubMed PMID: 7606882.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients. AU - Nishizawa,Y, AU - Shoji,T, AU - Emoto,M, AU - Kawasaki,K, AU - Konishi,T, AU - Tabata,T, AU - Inoue,T, AU - Morii,H, PY - 1995/4/1/pubmed PY - 1995/4/1/medline PY - 1995/4/1/entrez SP - 268 EP - 77 JF - Clinical nephrology JO - Clin. Nephrol. VL - 43 IS - 4 N2 - Elevated plasma intermediate density lipoprotein (IDL) is one of the features of uremic dyslipidemia which is potentially atherogenic. We examined the effects of pravastatin, an HMG-CoA reductase inhibitor, on IDL levels as well as other lipoprotein parameters in 19 uremic patients treated with hemodialysis (HD, n = 11) or continuous ambulatory peritoneal dialysis (CAPD, n = 8). The patients were administered 5 mg/day pravastatin for the initial 4 weeks and 10 mg/day for the subsequent 12 weeks. In the analysis of the total subjects, IDL-cholesterol was reduced by 31% as well as low density lipoprotein (LDL)-cholesterol. Cholesterol in very low density lipoprotein (VLDL) also decreased whereas that in high density lipoprotein (HDL) did not. Significant decrease of serum triglycerides was due mainly to reduced IDL- and LDL-triglycerides. Apolipoprotein (apo) A-I did not change, whereas apo A-II, B, C-II, C-III, E, and B/A-I ratio were significantly lowered. Pravastatin did not affect measured activity of lecithin: cholesterol acyltransferase, post-heparin plasma lipoprotein lipase or hepatic triglyceride lipase. HD and CAPD patients responded almost equally to the treatment. IDL elevation was present independent of serum total cholesterol, and it was lowered by pravastatin even in non-hypercholesterolemic subjects. There was no critical adverse effect besides transient and asymptomatic increase of serum creatine kinase level. We conclude that pravastatin can be a safe and effective approach to the management of dyslipidemia in uremic patients who have an elevated level of IDL. SN - 0301-0430 UR - https://www.unboundmedicine.com/medline/citation/7606882/Reduction_of_intermediate_density_lipoprotein_by_pravastatin_in_hemo__and_peritoneal_dialysis_patients_ L2 - https://medlineplus.gov/dialysis.html DB - PRIME DP - Unbound Medicine ER -